MARKET

KYNB

KYNB

KYNTRA BIO INC
NASDAQ
6.88
+0.18
+2.69%
Pre Market: 6.70 -0.18 -2.62% 08:45 06/23 EDT
OPEN
6.71
PREV CLOSE
6.70
HIGH
6.91
LOW
6.71
VOLUME
173
TURNOVER
--
52 WEEK HIGH
12.60
52 WEEK LOW
4.850
MARKET CAP
27.85M
P/E (TTM)
0.1700
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KYNB last week (0615-0619)?
Weekly Report · 1d ago
Kyntra Bio Shareholders Back Board, Pay and Auditor
TipRanks · 06/16 10:44
Kyntra Bio shareholders approved executive pay in advisory vote at annual meeting
PUBT · 06/16 10:02
Weekly Report: what happened at KYNB last week (0608-0612)?
Weekly Report · 06/15 09:16
Kyntra Reports Phase 3 MATTERHORN Data For Roxadustat In LR-MDS; U.S. Phase 3 Planned In H2 2026
NASDAQ · 06/12 15:01
Kyntra Bio to present additional MATTERHORN trial data at EHA
TipRanks · 06/11 20:20
Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardless Of Ring Sideroblast Status In Anemia Patients
Benzinga · 06/11 20:07
KYNTRA BIO PRESENTS NEW ROXADUSTAT DATA ON IMPROVEMENTS IN TRANSFUSION INDEPENDENCE REGARDLESS OF RING SIDEROBLAST STATUS IN PATIENTS WITH ANEMIA DUE TO LOWER-RISK MYELODYSPLASTIC SYNDROMES
Reuters · 06/11 20:05
More
About KYNB
Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

Webull offers Kyntra Bio Inc stock information, including NASDAQ: KYNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYNB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYNB stock methods without spending real money on the virtual paper trading platform.